A measured, harm-reduction look at testosterone undecanoate in both its very long-ester injectable and oral forms, and the bloodwork that actually matters.
At a glance
Testosterone undecanoate is a form of testosterone attached to a very long undecanoate ester. It exists as a long-acting injectable (sold as Nebido and Aveed) dosed roughly every 10 to 14 weeks after loading, and as an oral form (sold as Jatenzo and Kyzatrex) taken with food once or twice daily. It is used medically for testosterone replacement therapy (TRT) in men with diagnosed hypogonadism.
This is an educational tracking guide, not medical advice and not a recommendation. Testosterone undecanoate is a prescription medicine, and the discussion below is for tracking and harm reduction, not to encourage unsupervised use.
Testosterone undecanoate suppresses natural production and affects blood pressure, fertility, prostate, mood, lipids, and haematocrit; the oral form carries a specific blood pressure warning and the long injectable carries a rare microembolism risk. It is prescription-only for good reasons. Anyone using it should be monitored by a physician with regular, correctly timed bloodwork.
Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.